Effects of NO‐Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 5, 2015-11 ,pp. : 306-315

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results

By Voigt E.   Wasmuth J.-C.   Vogel M.   Mauss S.   Schmutz G.   Kaiser R.   Rockstroh J.-K.  

Infection, Vol. 32, Iss. 2, 2004-04 ,pp. : 82-88

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

By Cohen C.   Nieto-Cisneros L.   Zala C.   Fessel W. J.   Gonzalez-Garcia J.   Gladysz A.   McGovern R.   Adler E.   McLaren C.    

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1683-1692

Informa Healthcare

Access to resources Recommend Favorite

Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir‐containing regimens without sofosbuvir

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 126-133

John Wiley & Sons Inc

Access to resources Recommend Favorite

Serum concentrations of protease inhibitors as predictors of HIV-related clinical events in patients on antiretroviral therapy

By Ormaasen Vidar   Sandvik Leiv   Rudberg Nina   Bruun Johan  

Scandinavian Journal of Infectious Diseases, Vol. 38, Iss. 8, 2006-08 ,pp. : 650-653

Informa Healthcare

Access to resources Recommend Favorite